Agreement additional extension period option.

No definition available.

Name:	bbio_AgreementAdditionalExtensionPeriodOption
Namespace Prefix:	bbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Children intended for treatment with canavan disease maximum age.

+ References

No definition available.

+ Details

Name:	bbio_ChildrenIntendedForTreatmentWithCanavanDiseaseMaximumAge
Namespace Prefix:	bbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost sharing credit of the lesser of fixed percentage of certain agreed upon service costs.

+ References

No definition available.

+ Details

Name:	bbio_CostSharingCreditOfTheLesserOfFixedPercentageOfCertainAgreedUponServiceCosts
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cost sharing credits received.

+ References

No definition available.

+ Details

Name:	bbio_CostSharingCreditsReceived
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License fees.

+ References

No definition available.

+ Details

Name:	bbio_LicenseFees
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum required future payment upon achievement of certain development and milestone events net sales metrics.

+ References

No definition available.

+ Details

Name:	bbio_MaximumRequiredFuturePaymentUponAchievementOfCertainDevelopmentAndMilestoneEventsNetSalesMetrics
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential milestone payments.

+ References

No definition available.

+ Details

Name:	bbio_PotentialMilestonePayments
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Service agreement term.

+ References

No definition available.

+ Details

Name:	bbio_ServiceAgreementTerm
Namespace Prefix:	bbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=bbio_BridgeBioGeneTherapyLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bbio_AdrenasTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bbio_DevelopmentAndManufacturingServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bbio_ProjectAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bbio_ResilienceAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bbio_StanfordLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

In-licensing and Other Research and Development Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Aug. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total segment research and development		$ 111,231	$ 114,695	$ 222,662	$ 255,667
Children intended for treatment with Canavan Disease, under the age	5 years
BridgeBio Gene Therapy, LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum required future payment upon achievement of certain development and milestone events net sales metrics	$ 10,000
Adrenas
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum required future payment upon achievement of certain development and milestone events net sales metrics	$ 10,000
Resilience DMSAs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement term	10 years
Agreement additional extension period	2 years
Resilience PAs \| BridgeBio Gene Therapy, LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs	$ 15,500
Resilience PAs \| Adrenas
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs	$ 29,300
Resilience Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total segment research and development			400	1,200	900
Cost sharing credits received			$ 500		1,100
Eidos Therapeutics, Inc \| Stanford License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees		2,400		6,900	$ 8,100
Royalties on net product revenue		$ 1,100		$ 1,700
Milestone payments						$ 1,000